Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 208 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208. |
| Dose Expansion | EXPERIMENTAL | The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study. |
| Name | Type | Description |
|---|---|---|
| AMG 208 | DRUG | AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c-Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival. |
Inclusion Criteria: * Men or women ≥ 18 years old * Subjects must have a pathologically documented, definitively diagnosed, advanced solid tumor that is refractory to standard treatment, for which no standard therapy is available or the subject refuses standard therapy * Measurable disease per RECI...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AMG 208 is an investigational small molecule being studied for the treatment of cancer, specifically advanced solid tumors. It is being developed by Amgen Inc. (NASDAQ: AMGN) as a potential oncology therapy.
The specific molecular target of AMG 208 has not been disclosed in available information. It is a small molecule being investigated for its potential anti-cancer activity in patients with advanced solid tumors.
AMG 208 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The drug is currently in clinical development for the treatment of cancer.
AMG 208 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being evaluated for safety and efficacy in clinical trials.
AMG 208 has been studied in one completed Phase 1 clinical trial, identified as NCT00813384, titled "A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors." This trial enrolled 54 participants in the United States.
No alternative names for AMG 208 have been reported. It is identified solely by its investigational code name AMG 208 in clinical trial records and development documentation.